임상 레이더 AI
임상시험 NCT07396766 (BREASTChoice)은(는) 유방암, 유방 종양에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
검색으로 돌아가기

Dissemination of BREASTChoice AIM1-B 20

모집중
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07396766 (BREASTChoice)은(는) 유방암, 유방 종양에 대해 알아보는 중재연구입니다. 현재 상태는 모집중이며, 연구는 2025년 10월 1일에 시작되어 20명의 참여자를 모집하고 있습니다. UNC Lineberger Comprehensive Cancer Center이(가) 진행하며, 2029년 1월 20일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 2월 9일에 갱신되었습니다.
간단한 개요
This registration covers only Aim 1b, which focuses on testing usability. The study will include 20 participants who are breast cancer patients. Participants will be observed using the tool on their mobile devices, and their experience will be evaluated using a "think-aloud" method to capture their thoughts and reactions. Interviews will include open-ended questions about the content and format of the decision aid, w...더 보기
상세한 설명
This study is part of a larger project that will update and adapt an existing online decision tool called BREASTChoice. The project includes interviews and user testing with breast cancer survivors, interviews with medical experts, and updates to the website design.

Breast reconstruction after a mastectomy is an important part of breast cancer treatment. It can help restore quality of life and body image, which are ...

더 보기
공식 제목

Dissemination of a Breast Reconstruction Decision Tool Through Social Media and Online Communities- AIM1-B

질환명
유방암유방 종양
기타 연구 식별자
NCT 번호
NCT07396766
실제 연구 시작일
2025-10-01
최신 업데이트 게시
2026-02-09
예상 연구 완료일
2029-01-20
계획된 등록 인원
20
연구종류
중재연구
단계/상
해당 없음
상태
모집중
키워드
web-based patient decision aid
BREASTChoice
주요 목적
건강 서비스 연구
설계 할당
해당 없음
중재 모델
단일군설계
맹검 (마스킹)
없음 (오픈 라벨)
시험군 / 개입
참가자 그룹/시험군개입/치료
실험적Breast cancer survivors
Breast cancer survivors.
기본 설문지
Participants will be screened and share demographic information during screening. If eligible and screened in, the interviewer will send the self-administered pre-survey Decision Quality Index (DQI).
반구조화 면접
Participants will participate in a semi-structured interview and review of the adapted BREASTChoice tool.
Post Survey
Participants will take the post-survey to assess breast reconstruction decision quality.
주요결과변수
결과변수측정값 설명시간 범위
Change in breast reconstruction knowledge
This is knowledge based patient-reported outcome measure uses the Breast Cancer Reconstruction Decision Quality Instrument (DQI). DQ is a 9-item patient-reported measure designed to assess how well patients are informed about breast reconstruction options following breast cancer treatment. The instrument consists of multiple-choice questions with factual, correct answers related to breast reconstruction. Decision quality is quantified as a knowledge score, reflecting the extent to which patients understand key information necessary to make informed reconstruction decisions. Scores range from 0% to 100%. The total score is calculated by summing the number of correctly answered items and dividing by the total number of questions (9), with higher scores indicating greater knowledge and higher decision quality.
Up to1 week
참여 도우미
적격성 기준

Inclusions Criteria To participate in this study, a subject must meet all the eligibility criteria outlined below.

  • Age ≥ 18 years at the time of consent
  • Able to read and speak English.
  • Have had surgery, such as a mastectomy or lumpectomy, to remove some or all of their breast or breasts.
  • Breast surgery occurred within the past 8 years.
  • Breast surgery was due to a diagnosis of breast cancer, ductal carcinoma in situ, or risk of future breast cancer, by participant report.
  • Sex was assigned "Female" at birth

• Individuals with self-reported or observed unstable medical or psychiatric conditions precluding informed consent or participation in the study will be excluded.

UNC Lineberger Comprehensive Cancer Center logoUNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI) logo미국 국립암연구소
연구 대표 연락처
연락처: Victoria Triana, 919-966-4320, [email protected]
연락처: Kathryn A Chetwynd, 919-966-4320, [email protected]
1 1개국에 임상시험 장소

North Carolina

The University of North Carolina, Chapel Hill, North Carolina, 27599, United States
Kathryn A Chetwynd, 연락처, 919-966-4320, [email protected]
Clara Lee, MD, 책임연구자
모집중